NCT06704828View on ClinicalTrials.gov

A Phase II Study of SHR-4602 as Montherapy or in Combination With Other Anti-tumor Therapies in Advanced Solid Tumors

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

December 31, 2024

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2027

Conditions

Advanced Solid Tumors

Interventions

DRUG

SHR-4602

SHR-4602

Trial Locations (1)

100142

Beijing Cancer Hospital, Beijing

All Listed Sponsors

lead

Shanghai Hengrui Pharmaceutical Co., Ltd.

INDUSTRY